Clinical Research

Thumbnail

One adverse reaction to a GBCA significantly increases risk of another in the future

The type of gadolinium-based agent administered could also increase the risk of reaction, a new study suggests.

MDMA Ecstasy

FDA set to evaluate use of ‘ecstasy’ for treating PTSD

The party drug could soon be prescribed, in conjunction with psychological interventions, as a treatment for mental health disorders.

A newly identified PET imaging biomarker could help providers tailor immunotherapy treatments for patients with certain types of cancers.

Researchers identify new PET imaging biomarker capable of predicting immunotherapy success

A newly identified PET imaging biomarker could help providers tailor immunotherapy treatments for patients with certain types of cancers. 

How beneficial is MR-directed breast ultrasound in reducing biopsies?

A team of experts determined that correlating masses initially detected on MRI are significantly more likely to result in a cancer diagnosis than other common findings. 

HRS 2024: Late-breaking clinical trials will highlight key trends in electrophysiology

A total of 21 late-breaking science presentations are scheduled for Heart Rhythm 2024 in Boston. 

Thumbnail

Point-based risk prediction model reduces prostate biopsies by up to 20%

The model incorporates specific data from MRI exams with patient risk factors to predict whether a person is likely to develop clinically significant prostate cancer.

AI for diabetic retinopathy

GPT-4 now has vision—can it actually read chest X-rays?

Finely tuned, pre-trained large language models are beginning to reliably translate image content into text, but are they ready to take on medical images? 

Interview with Nehal Mehta, MD, Penn Medicine, who explains how coronary inflammation can be seen using AI on cardiac CT scans to better risk stratify patients and begin preventive drug therapy.

AI helps cardiologists track new drug's effect on inflammation

The combination of AI and CT helped Nehal Mehta, MD, and colleagues track the performance of a new drug designed to target coronary inflammation.